Edwards Lifesciences (EW) Tops Q1 EPS by 4c, Offers Guidance

Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.64, $0.04 better than the analyst estimate of $0.60. Revenue for the quarter came in at $1.41 billion versus the consensus estimate of $1.4 billion.

GUIDANCE:

Edwards Lifesciences sees FY2025 EPS of $2.40-$2.50, versus the consensus of $2.45.

Edwards Lifesciences sees Q2 2025 EPS of $0.59-$0.65, versus the consensus of $0.62. Edwards Lifesciences sees Q2 2025 revenue of $1.45-1.53 billion, versus the consensus of $1.47 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• GameStop CEO Cohen buys 1.15M shares
• Citizens Upgrades Quince Therapeutics Inc. (QNCX) to Market Outperform
• Jefferies Downgrades Marathon Petroleum (MPC) to Hold